Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial is a research paper published in Nature (2018). On theSindex it has a DataRank of 1.1. It has been cited 1,412 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
1.1
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NCI NIH HHS
Grant: 2P50CA101942-11A1
DF/HCC Kidney Cancer SPORE
NCI NIH HHS
Grant: R21 CA216772
NCI NIH HHS
Grant: R50 CA211482
NCI NIH HHS
Grant: R01 CA155010
NCI NIH HHS
Grant: R21 CA216772-01A1
NCI NIH HHS
Grant: T32 CA207021
NHLBI NIH HHS
Grant: 5R01HL103532-03
Post-transplant vaccines to enhance graft-versus-leukemia responses
NCI NIH HHS
Grant: P50 CA101942
NCI NIH HHS
Grant: 1R01CA155010-02
NHLBI NIH HHS
Grant: R01 HL103532
NCI NIH HHS
Grant: P01 CA163205
NCI NIH HHS
Grant: P50 CA165962
NCI NIH HHS
Grant: R01 CA279391
Lundbeck Foundation
Grant: R181-2014-3761
NHLBI NIH HHS
Grant: T32 HL007627
National Institutes of Health
Grant: 5R01CA155010-02
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia
National Institutes of Health
Grant: 3P01CA163205-03S1
Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas
National Institutes of Health
Grant: 1R21CA216772-01A1
Physical detection of HLA-C binding peptides to identify and predict immunogenic personal neoepitopes for improving cancer vaccines
National Institutes of Health
Grant: 5T32HL007627-27
Vascular, Pulmonary and Renal Injury
National Institutes of Health
Grant: 5R50CA211482-03
Immunogenomic analytical approaches for research and clinical applications
National Institutes of Health
Grant: 4P50CA165962-04
SPORE: Targeted Therapies for Glioma
Howard Hughes Medical Institute
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 2 of Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy
Additional file 2 of Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy
Additional file 2 of Comparison of personal and shared frameshift neoantigen vaccines in a mouse mammary cancer model
Additional file 2 of Comparison of personal and shared frameshift neoantigen vaccines in a mouse mammary cancer model
Additional file 1 of Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation
Additional file 1 of Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation
Additional file 3 of Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation
Additional file 3 of Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation
Additional file 1 of Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal
Additional file 1 of Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal
Additional file 1 of Cerebrospinal fluid cytokine levels are associated with macrophage infiltration into tumor tissues of glioma patients
Additional file 1 of Cerebrospinal fluid cytokine levels are associated with macrophage infiltration into tumor tissues of glioma patients
Additional file 10 of Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion
Additional file 10 of Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion
Additional file 12 of Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion
Additional file 12 of Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion
Additional file 13 of Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion
Additional file 13 of Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion
Additional file 14 of Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion
Additional file 14 of Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion